Dina Abushanab, Wafa Al-Marridi, Moza Al Hail, Palli Valappila Abdul Rouf, Wessam ElKassem, Binny Thomas, Hussam Alsoub, Zanfina Ademi, Yolande Hanssens, Rasha El Enany, Daoud Al-Badriyeh
{"title":"卡塔尔成人全科医疗机构制定抗菌药物管理计划的相关成本。","authors":"Dina Abushanab, Wafa Al-Marridi, Moza Al Hail, Palli Valappila Abdul Rouf, Wessam ElKassem, Binny Thomas, Hussam Alsoub, Zanfina Ademi, Yolande Hanssens, Rasha El Enany, Daoud Al-Badriyeh","doi":"10.1080/20523211.2024.2326382","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To estimate the economic impact of the developed antimicrobial stewardship program (ASP) versus the preliminary ASP use, in the adults' general medicine settings in Qatar.</p><p><strong>Methods: </strong>Patient records were retrospectively reviewed during two periods: preliminary ASP was defined as the 12 months following ASP implementation (i.e. May 2015-April 2016), and developed ASP was defined as the last 12 months of a 5-year ASP implementation in Hamad Medical Corporation (HMC) (i.e. February 2019-January 2020). The economic impact was the overall cost savings in resource use, including operational costs, plus the cost avoidance associated with ASP.</p><p><strong>Results: </strong>A total of 500 patients were included in the study. The operational costs decreased with the developed ASP. Whereas antimicrobial consumption and resource utilisation, and their associated costs, appear to have declined with the developed ASP, with a cost saving of QAR458 (US$125) per 100-patient beds, the avoided cost was negative, by QAR4,807 (US$1,317) per 100-patient beds, adding to a total QAR4,224 (US$1,160) increase in the 100-patient beds cost after ASP development.</p><p><strong>Conclusions: </strong>Despite that the developed ASP attained a total cost saving QAR458 (US$125) per 100-patient beds, the avoided cost was QAR-4,807 (US$-1,317) per 100-patient beds, which exceeded the cost savings achieved.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2326382"},"PeriodicalIF":3.3000,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977017/pdf/","citationCount":"0","resultStr":"{\"title\":\"The cost associated with the development of the antimicrobial stewardship program in the adult general medicine setting in Qatar.\",\"authors\":\"Dina Abushanab, Wafa Al-Marridi, Moza Al Hail, Palli Valappila Abdul Rouf, Wessam ElKassem, Binny Thomas, Hussam Alsoub, Zanfina Ademi, Yolande Hanssens, Rasha El Enany, Daoud Al-Badriyeh\",\"doi\":\"10.1080/20523211.2024.2326382\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To estimate the economic impact of the developed antimicrobial stewardship program (ASP) versus the preliminary ASP use, in the adults' general medicine settings in Qatar.</p><p><strong>Methods: </strong>Patient records were retrospectively reviewed during two periods: preliminary ASP was defined as the 12 months following ASP implementation (i.e. May 2015-April 2016), and developed ASP was defined as the last 12 months of a 5-year ASP implementation in Hamad Medical Corporation (HMC) (i.e. February 2019-January 2020). The economic impact was the overall cost savings in resource use, including operational costs, plus the cost avoidance associated with ASP.</p><p><strong>Results: </strong>A total of 500 patients were included in the study. The operational costs decreased with the developed ASP. Whereas antimicrobial consumption and resource utilisation, and their associated costs, appear to have declined with the developed ASP, with a cost saving of QAR458 (US$125) per 100-patient beds, the avoided cost was negative, by QAR4,807 (US$1,317) per 100-patient beds, adding to a total QAR4,224 (US$1,160) increase in the 100-patient beds cost after ASP development.</p><p><strong>Conclusions: </strong>Despite that the developed ASP attained a total cost saving QAR458 (US$125) per 100-patient beds, the avoided cost was QAR-4,807 (US$-1,317) per 100-patient beds, which exceeded the cost savings achieved.</p>\",\"PeriodicalId\":16740,\"journal\":{\"name\":\"Journal of Pharmaceutical Policy and Practice\",\"volume\":\"17 1\",\"pages\":\"2326382\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977017/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Policy and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/20523211.2024.2326382\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2024.2326382","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0
摘要
目的估算在卡塔尔成人全科医疗机构中,已制定的抗菌药物管理计划(ASP)与初步ASP使用的经济影响:对两个时期的患者病历进行了回顾性审查:初步 ASP 定义为实施 ASP 后的 12 个月(即 2015 年 5 月至 2016 年 4 月),已制定 ASP 定义为哈马德医疗公司(HMC)实施为期 5 年的 ASP 的最后 12 个月(即 2019 年 2 月至 2020 年 1 月)。经济影响是指资源使用的总体成本节约,包括运营成本,以及与 ASP 相关的成本避免:研究共纳入了 500 名患者。开发的 ASP 降低了运营成本。虽然抗菌素的消耗和资源的使用及其相关成本似乎随着所开发的 ASP 而下降,每 100 张病床节省了 458 卡里亚尔(125 美元),但所避免的成本却是负数,每 100 张病床减少了 4,807 卡里亚尔(1,317 美元),而在开发 ASP 后,每 100 张病床的成本总共增加了 4,224 卡里亚尔(1,160 美元):结论:尽管所开发的 ASP 实现了每 100 张病床节省 458 卡里亚尔(125 美元)的总成本,但每 100 张病床所避免的成本为 4 807 卡里亚尔(1 317 美元),超过了所节省的成本。
The cost associated with the development of the antimicrobial stewardship program in the adult general medicine setting in Qatar.
Objective: To estimate the economic impact of the developed antimicrobial stewardship program (ASP) versus the preliminary ASP use, in the adults' general medicine settings in Qatar.
Methods: Patient records were retrospectively reviewed during two periods: preliminary ASP was defined as the 12 months following ASP implementation (i.e. May 2015-April 2016), and developed ASP was defined as the last 12 months of a 5-year ASP implementation in Hamad Medical Corporation (HMC) (i.e. February 2019-January 2020). The economic impact was the overall cost savings in resource use, including operational costs, plus the cost avoidance associated with ASP.
Results: A total of 500 patients were included in the study. The operational costs decreased with the developed ASP. Whereas antimicrobial consumption and resource utilisation, and their associated costs, appear to have declined with the developed ASP, with a cost saving of QAR458 (US$125) per 100-patient beds, the avoided cost was negative, by QAR4,807 (US$1,317) per 100-patient beds, adding to a total QAR4,224 (US$1,160) increase in the 100-patient beds cost after ASP development.
Conclusions: Despite that the developed ASP attained a total cost saving QAR458 (US$125) per 100-patient beds, the avoided cost was QAR-4,807 (US$-1,317) per 100-patient beds, which exceeded the cost savings achieved.